top of page

Dr. Jennifer Chan Announces the CABINET Trial Data on Cabozantinib

On Oct 22, 2023, Dr. Jennifer Chan from Dana Farber Cancer Institute shared the CABINET trial data that showed cabozantinib (CABOMETYX®) helped those with advanced pancreatic NET and extrapancreatic NET (NET outside the pancreas). The results suggest that cabozantinib may be an effective option to treat NET patients, even those who have already tried other therapies. Exelis will discuss the results with the FDA. The NET patient community can be hopeful that there will likely be another FDA-approved oral treatment available in the near future.

Click here to read the detailed results of the CABINET trial here:

Business Wire - "Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023"

OncLive - "Cabozantinib Confers PFS Benefit in Previously Treated Advanced Neuroendocrine Tumors"

Watch this exclusive video interview with Dr. Jennifer Chan at ESMO - European Society for Medical Oncology 2023 in Madrid, Spain.

Visit our Clinical Trials Guide for more information about the CABINET Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced NETs After Progression on Prior Therapy >>

170 views0 comments

Recent Posts

See All
bottom of page